Medication info
Rocanduo Tablets 5/16 mg

Rocanduo Tablets 5/16 mg

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›5.2mg / 1 tabletCandesartan Cilexetil›16mg / 1 tablet
Manufacturer / importer
Albozen Korea Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
30 tablets (10 tablets/PTP X 3)
Approval status
Active

MFDS item code 201803500 · Approved 2018.08.28 · Insurance code 652606510

Summary

Main use
Treatment of hypertension and heart failure; suppression of dyslipidemia and atherosclerosis; prevention of cardiovascular disease
Who takes it
Adults · Children
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the effects and tolerability of each component, candesartan cilexetil and rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatments should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: Administer an initial dose of 4 mg with particular caution in patients at increased risk of hypotension, such as those with volume depletion. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including those undergoing hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience in patients with severe hepatic impairment. 2. Heart failure 1) Adults: An initial dose of 4 mg once daily is recommended. Double the dose at intervals of at least 2 weeks and, based on the patient's tolerability, increase it to a maximum of 32 mg once daily. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue the diet throughout treatment. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score exceeding 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.
Child dose
Adolescents and children 18 years of age or younger: Safety and efficacy have not been established. Adolescents and children 18 years of age or younger: Safety and efficacy have not been established.

Ingredients

Manufacturer
Albozen Korea Co., Ltd.

Efficacy & effects

Treatment of hypertension and heart failure; suppression of dyslipidemia and atherosclerosis; prevention of cardiovascular disease

  • Essential hypertension
  • heart failure
  • hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol
  • smoking
  • family history of early coronary artery disease
View approved original text

This medication is used for patients who require simultaneous administration of Candesartan Cilexetil and Rosuvastatin. Candesartan Cilexetil is mainly used in patients with essential hypertension or heart failure with impaired left ventricular systolic function when additional ACE inhibitor treatment is needed or is not tolerated well. Rosuvastatin is used as an adjunct to diet in patients with hypercholesterolemia and various types of dyslipidemia, especially to delay the progression of atherosclerosis and reduce the risk of cardiovascular diseases. It also reduces the risk of stroke, myocardial infarction, and arterial revascularization and is useful for patients at high risk for cardiovascular diseases. The combination therapy of these two medications effectively improves the health status of patients by managing hypertension, dyslipidemia, and cardiovascular risk factors together.

How to take

Adult dose

This medicine is for use in adults only. The dose should be individualized for each patient based on the effects and tolerability of each component, candesartan cilexetil and rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatments should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: Administer an initial dose of 4 mg with particular caution in patients at increased risk of hypotension, such as those with volume depletion. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including those undergoing hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience in patients with severe hepatic impairment. 2. Heart failure 1) Adults: An initial dose of 4 mg once daily is recommended. Double the dose at intervals of at least 2 weeks and, based on the patient's tolerability, increase it to a maximum of 32 mg once daily. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue the diet throughout treatment. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score exceeding 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.

Child dose

Adolescents and children 18 years of age or younger: Safety and efficacy have not been established. Adolescents and children 18 years of age or younger: Safety and efficacy have not been established.

Precautions

This medication can cause serious harm especially to the fetus during pregnancy, so it should be discontinued immediately if pregnancy is confirmed. Patients with an allergy to this medication or its components, patients with severe liver impairment, women who are pregnant or breastfeeding, and patients with muscle diseases should not take this medication. Elderly patients, patients with hyperkalemia, liver disease, and cardiovascular disease need to be cautious during administration, and regular blood tests and physical state monitoring are required. This medication may cause serious muscle-related side effects such as myalgia, myopathy, and rarely, rhabdomyolysis; therefore, if muscle pain or weakness occurs, a doctor should be consulted immediately. Liver function abnormalities may occur, so regular liver function tests should be performed before and during administration, and the medication should be stopped if liver enzyme levels rise significantly. This medication may interact with other drugs, especially potassium-sparing diuretics, lithium, certain antibiotics, antifungals, and immunosuppressants, so inform your doctor when taking these medications together. It is advisable not to take this medication while breastfeeding and, if unavoidable, to discontinue breastfeeding. In case of an overdose, symptoms such as hypotension, dizziness, and increased heart rate may occur, and immediate medical attention should be sought. Be cautious as dizziness or malaise may occur while driving or operating machinery. Keep out of reach of children, and do not transfer medications to other containers.

Side effects

headache, nasopharyngitis, local infection, fatigue, generalized pruritus, dermatitis, itching, joint stiffness, limb pain, photophobia, dyspepsia, elevated blood glucose, decreased serum sodium, hand fracture, hypoglycemia, nephrolithiasis, cough, headache, itching, nausea, dizziness, orthostatic dizziness, miliaria, periodontitis, inflammation, foreign body sensation, musculoskeletal pain, neck pain, cataract, elevated blood glucose, decreased serum sodium, hand fracture, hypoglycemia, nephrolithiasis, cough, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, vascular edema, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disturbance, interstitial lung disease, sexual dysfunction, gynecomastia, impaired memory, forgetfulness, amnesia, memory disorder, confusion, paralysis, hypertonicity, syncope, facial flushing, weight gain, facial edema, thirst, sleep disturbance, decreased libido, forgetfulness, anorexia, increased appetite, tinnitus, taste disturbance, erectile dysfunction, dizziness, orthostatic dizziness, hypotension, hyperkalemia, impaired renal function, increased creatinine, increased urea, increased potassium, decreased sodium, elevated ALT, elevated liver enzymes, hepatic dysfunction, jaundice, blood and lymphatic system abnormalities, leukopenia, neutropenia, agranulocytosis, hyperkalemia, hyponatremia, hypoglycemia, weakness, hunger, cold sweats, hand tremor, decreased concentration, convulsions, altered consciousness, pneumonia, intestinal vascular edema, diarrhea, hepatitis, rash, urticaria, vascular edema, rhabdomyolysis, arthralgia, myalgia, low back pain, impaired renal function, acute kidney failure, interstitial pneumonia, shock, syncope, loss of consciousness, thrombocytopenia, femoral fracture, contusion, unstable angina, idiopathic pulmonary fibrosis, worsening hypertension, unstable blood pressure, vertigo, orthostatic vertigo, adrenal insufficiency

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly sealed container to protect it from air and moisture, at room temperature between 1°C and 30°C. Storing it this way can help maintain the medication's effectiveness for a longer time.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

30 tablets (10 tablets/PTP X 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.